Immunotherapy duo targets rare, Mutation-Rich breast cancer
NCT ID NCT03789110
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 30 people with a rare, advanced form of HER2-negative breast cancer that has many genetic mutations (hypermutated). The goal was to see if this drug pair could shrink or control the cancer. Participants received the drugs intravenously, and the study measured how many people's tumors responded to treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?